NeurologyLive® Friday 5 — March 22, 2024

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 22, 2024.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: #PreAANChat: NeurologyLive to Host Pre-AAN 2024 Social Chat

Join us on April 8, 2024, for a social chat ahead of the 2024 American Academy of Neurology Annual Meeting! We will be discussing top sessions, tips and tricks for first-time attendees, and what everyone is looking forward to most at this year’s meeting!

#PreAANChat: NeurologyLive to Host Pre-AAN 2024 Social Chat

2: IJMSC Online First: March 2024

Here's the latest multidisciplinary multiple sclerosis research published online first in the International Journal of MS Care.

IJMSC Online First: March 2024

3: Exploring the Potential Therapeutic Avenue of BTK Inhibitors for Progressive MS: Amit Bar-Or, MD, FRCPC, FAAN, FANA

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, discussed the promising avenue of BTK inhibitors for addressing progressive multiple sclerosis. [WATCH TIME: 5 minutes]

Exploring the Potential Therapeutic Avenue of BTK Inhibitors for Progressive MS: Amit Bar-Or, MD, FRCPC, FAAN, FANA

4: NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

In this week's NeuroVoices Q&A, the chief executive officer at Elixirgen Therapeutics provided commentary on the promise of the Bobcat mRNA, and the mechanism of action for mRNA-like therapies to treat Duchenne muscular dystrophy.

NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy

5: Emerging Class of Medications for Multiple Sclerosis: Examining the Development of BTK Inhibitors

A panel of experts MS specialists provided commentary on the clinical development of these therapies, some of the specific agents within the pipeline, and how to navigate potential safety concerns.

 Emerging Class of Medications for Multiple Sclerosis: Examining the Development of BTK Inhibitors
Related Videos
Kevin Church, PhD
Merit Cudkowicz, MD, MSc
Jessica Ailani, MD
Frederic Schaper, MD, PhD
Jaime Imitol, MD
© 2024 MJH Life Sciences

All rights reserved.